Azelby Robert 4
4 · Tango Therapeutics, Inc. · Filed Jun 23, 2026
Research Summary
AI-generated summary of this filing
Tango Therapeutics (TNGX) Director Robert Azelby Receives Awards
What Happened
Robert Azelby, a director of Tango Therapeutics (TNGX), received equity awards on June 19, 2026. The filing shows an award of 5,740 restricted stock units (RSUs) and a derivative award of 35,910 shares (an option-like derivative), each recorded at $0.00 (grant/award). These are grants (transaction code A) rather than open-market purchases or sales.
Key Details
- Transaction date: 2026-06-19; reported on Form 4 filed 2026-06-23 (timely filed).
- Price: $0.00 for both awards (standard for grants/RSUs/options at grant).
- Award amounts: 5,740 RSUs + 35,910-share derivative award (total 41,650 share-equivalents granted).
- Vesting/terms noted in footnotes:
- F1 (RSUs): the 5,740 RSUs convert to one share each and vest in three substantially equal annual installments, subject to continued service.
- F2 (option/derivative): the derivative award vests in 36 substantially equal monthly installments over three years, subject to continued service.
- Shares owned after the transaction: not specified in the provided filing excerpt.
- Filing timeliness: Filed 6/23/2026 for a 6/19/2026 grant — within the standard two-business-day reporting window.
Context
These entries reflect equity compensation (awards/vesting schedules), not purchases or sales. RSU grants and option awards give the recipient a future right to shares if vesting conditions are met; they do not by themselves indicate buying or selling activity or immediate cash flows. Such grants are common for executives/directors as part of compensation packages.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-19+5,740→ 5,740 total - Award
Stock Option (Right to Buy)
[F2]2026-06-19+35,910→ 35,910 totalExercise: $27.97Exp: 2036-06-19→ Common Stock (35,910 underlying)
Footnotes (2)
- [F1]These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in three substantially equal annual installments following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
- [F2]This option shall vest and become exercisable in 36 substantially equal monthly installments over a period of three years following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.